Baltimore biotech Elixirgen Therapeutics making drugs to target rare diseases, raises $4 million - Baltimore Business Journal

A Baltimore biotechnology company has raised $4 million, to help bring its therapeutic treatment targeting rare genetic diseases closer to market.